Literature DB >> 27864095

Optimization of an in vitro chemotherapy to avoid resistant tumours.

Cécile Carrère1.   

Abstract

Chemotherapy use against solid tumours often results in the resistance of the cancer cells to the molecule used. In this paper, we will set up and analyse an ODE model for heterogeneous in vitro tumours, consisting of cells that are sensitive or resistant to a certain drug. We will then use this model to develop different protocols, that aim at reducing the tumour volume while preserving its heterogeneity. These drug administration schedules are determined through analysis of the system dynamics, and optimal control theory. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Mathematical model; Metronomics; Optimal control

Mesh:

Substances:

Year:  2016        PMID: 27864095     DOI: 10.1016/j.jtbi.2016.11.009

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  8 in total

Review 1.  The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer.

Authors:  Benjamin Wölfl; Hedy Te Rietmole; Monica Salvioli; Artem Kaznatcheev; Frank Thuijsman; Joel S Brown; Boudewijn Burgering; Kateřina Staňková
Journal:  Dyn Games Appl       Date:  2021-08-30       Impact factor: 1.296

2.  Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory.

Authors:  Mark Gluzman; Jacob G Scott; Alexander Vladimirsky
Journal:  Proc Biol Sci       Date:  2020-04-22       Impact factor: 5.530

Review 3.  Cell plasticity in cancer cell populations.

Authors:  Shensi Shen; Jean Clairambault
Journal:  F1000Res       Date:  2020-06-22

4.  Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.

Authors:  James M Greene; Jana L Gevertz; Eduardo D Sontag
Journal:  JCO Clin Cancer Inform       Date:  2019-04

5.  Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.

Authors:  Jessica Cunningham; Frank Thuijsman; Ralf Peeters; Yannick Viossat; Joel Brown; Robert Gatenby; Kateřina Staňková
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

6.  Combination treatment optimization using a pan-cancer pathway model.

Authors:  Robin Schmucker; Gabriele Farina; James Faeder; Fabian Fröhlich; Ali Sinan Saglam; Tuomas Sandholm
Journal:  PLoS Comput Biol       Date:  2021-12-28       Impact factor: 4.475

7.  Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer.

Authors:  Maryna Bondarenko; Marion Le Grand; Yuval Shaked; Ziv Raviv; Guillemette Chapuisat; Cécile Carrère; Marie-Pierre Montero; Mailys Rossi; Eddy Pasquier; Manon Carré; Nicolas André
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

8.  Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.

Authors:  Philip K Maini; Alexander R A Anderson; Maximilian A R Strobl; Jeffrey West; Yannick Viossat; Mehdi Damaghi; Mark Robertson-Tessi; Joel S Brown; Robert A Gatenby
Journal:  Cancer Res       Date:  2020-11-10       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.